Objective
To investigate the frequencies of opportunistic infections and malignancies associated with European AIDS patients diagnosed from 1979 to 1989, and to relate these findings to the demographic and clinical data including survival.
In order to investigate the frequencies of opportunistic infections and malignancies and in order to correlate these findings to demographic and clinical data in European acquired immunedeficiency syndrome (AIDS) patients, a multicentre European Community EC supported study was initiated. At the end of the data collecting phase in February 1992, a total of 52 centres from 17 countries participated in the study by providing detailed information on AIDS patients from the 10 years period to the data handling centre in Copenhagen. The database includes clinical and therapeutical information on 6578 than European AIDS patients.
The overall median survival from the time of AIDS diagnosis was 17 months.
Patients diagnosed in south Europe had a shorter survival than patients from central and north Europe.
An improved survival for patients diagnosed with AIDS in 1987 compared to earlier diagnosis was observed.
Zidovudine was introduced in the clinical management of patients with advanced HIV infection in 1987.
Patients who started zidovudine after the time of the AIDS diagnosis had a decreased risk of dying within the first 1-2 years after time of initiation of therapy compared to untreated patients. However, the effect seems to be limited to 2 years after starting therapy.
There appears to be only minor differences between men and women in the clinical course of AIDS.
For patients with Kaposi's sarcoma (KS) as their initial diagnosis, no improvement in survival time was observed.
Pneumocystis carinii pneumonia (PCP) is the leading complication to the HIV infection.
Improvement in survival from the pneumonia may be due to increased awareness of early symptoms of PCP and improved treatment, whereas the introduction of zidovudine and the routine use of secondary PCP prophylaxis may be responsible for the increased survival 1 and 2 years after the diagnosis observed in recent years.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine pneumology
- natural sciences computer and information sciences databases
- medical and health sciences health sciences infectious diseases RNA viruses HIV
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
2650 Hvidovre
Denmark
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.